DE60132782T2 - Prodrugs zu nmda-rezeptorliganden - Google Patents

Prodrugs zu nmda-rezeptorliganden Download PDF

Info

Publication number
DE60132782T2
DE60132782T2 DE60132782T DE60132782T DE60132782T2 DE 60132782 T2 DE60132782 T2 DE 60132782T2 DE 60132782 T DE60132782 T DE 60132782T DE 60132782 T DE60132782 T DE 60132782T DE 60132782 T2 DE60132782 T2 DE 60132782T2
Authority
DE
Germany
Prior art keywords
compound
formula
hydroxy
benzyl
ethanesulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60132782T
Other languages
German (de)
English (en)
Other versions
DE60132782D1 (de
Inventor
Alexander Alanine
Bernd Buettelmann
Holger Fisher
Marie-Paule Heitz Neidhart
Joerg Huwyler
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60132782D1 publication Critical patent/DE60132782D1/de
Publication of DE60132782T2 publication Critical patent/DE60132782T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE60132782T 2000-08-21 2001-08-20 Prodrugs zu nmda-rezeptorliganden Expired - Lifetime DE60132782T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00117918 2000-08-21
EP00117918 2000-08-21
PCT/EP2001/009561 WO2002016321A1 (en) 2000-08-21 2001-08-20 Prodrugs to nmda receptor ligands

Publications (2)

Publication Number Publication Date
DE60132782D1 DE60132782D1 (de) 2008-03-27
DE60132782T2 true DE60132782T2 (de) 2009-02-05

Family

ID=8169594

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60132782T Expired - Lifetime DE60132782T2 (de) 2000-08-21 2001-08-20 Prodrugs zu nmda-rezeptorliganden

Country Status (35)

Country Link
US (1) US6407235B1 (cg-RX-API-DMAC7.html)
EP (1) EP1313703B1 (cg-RX-API-DMAC7.html)
JP (1) JP4162991B2 (cg-RX-API-DMAC7.html)
KR (1) KR100589991B1 (cg-RX-API-DMAC7.html)
CN (1) CN1227230C (cg-RX-API-DMAC7.html)
AR (1) AR030373A1 (cg-RX-API-DMAC7.html)
AT (1) ATE386022T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001285894B2 (cg-RX-API-DMAC7.html)
BR (1) BR0113348A (cg-RX-API-DMAC7.html)
CA (1) CA2419279C (cg-RX-API-DMAC7.html)
CY (1) CY1107937T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303319B6 (cg-RX-API-DMAC7.html)
DE (1) DE60132782T2 (cg-RX-API-DMAC7.html)
DK (1) DK1313703T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP034489A (cg-RX-API-DMAC7.html)
EG (1) EG24293A (cg-RX-API-DMAC7.html)
ES (1) ES2299508T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20030125B1 (cg-RX-API-DMAC7.html)
HU (1) HU229802B1 (cg-RX-API-DMAC7.html)
IL (1) IL154254A0 (cg-RX-API-DMAC7.html)
JO (1) JO2289B1 (cg-RX-API-DMAC7.html)
MA (1) MA26947A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03001311A (cg-RX-API-DMAC7.html)
MY (1) MY136065A (cg-RX-API-DMAC7.html)
NO (1) NO324941B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ523990A (cg-RX-API-DMAC7.html)
PA (1) PA8525601A1 (cg-RX-API-DMAC7.html)
PE (1) PE20020291A1 (cg-RX-API-DMAC7.html)
PL (1) PL204215B1 (cg-RX-API-DMAC7.html)
PT (1) PT1313703E (cg-RX-API-DMAC7.html)
RS (1) RS51467B (cg-RX-API-DMAC7.html)
RU (1) RU2272027C2 (cg-RX-API-DMAC7.html)
SI (1) SI1313703T1 (cg-RX-API-DMAC7.html)
WO (1) WO2002016321A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200300894B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2245876C2 (ru) * 2000-03-21 2005-02-10 Дзе Проктер Энд Гэмбл Компани Производные сульфонамидов и фармацевтическая композиция на их основе
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
CN101374801B (zh) * 2005-12-19 2014-07-02 梅特希尔基因公司 用于增强抗真菌剂活性的组蛋白脱乙酰酶抑制剂
JP2010513326A (ja) 2006-12-19 2010-04-30 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
KR102336426B1 (ko) 2013-11-05 2021-12-08 아스트라제네카 아베 Nmda 길항제 전구약물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9408506A (pt) * 1994-01-31 1997-08-05 Pfizer Compostos neuroprotetores
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor

Also Published As

Publication number Publication date
CA2419279C (en) 2008-10-14
HUP0301548A3 (en) 2010-03-29
EP1313703A1 (en) 2003-05-28
JO2289B1 (en) 2005-09-12
NO324941B1 (no) 2008-01-07
KR20030022417A (ko) 2003-03-15
CA2419279A1 (en) 2002-02-28
SI1313703T1 (sl) 2008-06-30
RU2272027C2 (ru) 2006-03-20
PE20020291A1 (es) 2002-04-17
KR100589991B1 (ko) 2006-06-15
EP1313703B1 (en) 2008-02-13
CZ303319B6 (cs) 2012-08-01
YU13003A (sh) 2006-05-25
JP4162991B2 (ja) 2008-10-08
NZ523990A (en) 2004-09-24
PL361387A1 (en) 2004-10-04
CN1447793A (zh) 2003-10-08
AU2001285894B2 (en) 2006-06-15
HRP20030125A2 (en) 2005-02-28
BR0113348A (pt) 2003-07-08
US6407235B1 (en) 2002-06-18
ZA200300894B (en) 2004-04-30
JP2004506715A (ja) 2004-03-04
CN1227230C (zh) 2005-11-16
PT1313703E (pt) 2008-03-25
AR030373A1 (es) 2003-08-20
MA26947A1 (fr) 2004-12-20
AU8589401A (en) 2002-03-04
HK1059083A1 (en) 2004-06-18
DK1313703T3 (da) 2008-05-19
PL204215B1 (pl) 2009-12-31
EG24293A (en) 2009-01-08
RS51467B (sr) 2011-04-30
NO20030781D0 (no) 2003-02-19
CZ2003492A3 (cs) 2004-01-14
ES2299508T3 (es) 2008-06-01
MXPA03001311A (es) 2003-06-30
WO2002016321A1 (en) 2002-02-28
PA8525601A1 (es) 2002-04-25
HUP0301548A2 (hu) 2003-08-28
NO20030781L (no) 2003-02-19
DE60132782D1 (de) 2008-03-27
CY1107937T1 (el) 2013-09-04
US20020040037A1 (en) 2002-04-04
ATE386022T1 (de) 2008-03-15
MY136065A (en) 2008-08-29
HU229802B1 (hu) 2014-07-28
IL154254A0 (en) 2003-09-17
HRP20030125B1 (en) 2011-07-31
ECSP034489A (es) 2003-03-31

Similar Documents

Publication Publication Date Title
DE69027794T2 (de) N-Phenyl-N-(4-piperidinyl)-amide, verwendbar als Analgetika
EP0207331B1 (de) Neue feste Formen von 2-Äthoxy-4-[N-(1-(2-piperidino-phenyl)-3-methyl-1-butyl)-aminocarbonylmethyl]-benzoesäure, diese Formen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE69518194T2 (de) Hydroxamsäure-Derivate mit drei Ringsubstituenten
DE69529418T2 (de) Cyclopropachromencarbonsäure derivate
DE60116080T2 (de) 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidin-3,4-diol
DE60006340T2 (de) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid
EP0888313A1 (de) 2,3-benzodiazepinderivate und deren verwendung als ampa-rezeptoren-hemmer
DD149071A5 (de) Herstellung 2-substituierter trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido eckige klammer auf 4,3-b eckige klammer zu indole
DE60034577T2 (de) In 4-stellung substituierte piperidinderivate
EP0645390A1 (de) Trisubstituierte Pyrimido/5,4-d/-pyrimidine zur Modulation der Multidrugresistenz, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE60013225T2 (de) 4-Hydroxy-4-Phenylpiperidin-Derivate mit opioid-agonistischer Aktivität und di ese enthaltende Pharmazeutika
DE60025348T2 (de) Ethansulfonyl-piperidin-derivate
DE69311123T2 (de) Cyclische benzylamino-, benzylamido- und benzylimido derivate als antipsychotische wirkstoffe
EP0389425B1 (de) Neue Benzothiopyranylamine
US6407235B1 (en) Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol
EP0002672A2 (de) Substituierte Pyrrolidine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
DE69827614T2 (de) Chinoxalindionen
EP0409119A1 (de) N,N'-Bis(alkoxy-alkyl)-pyridin-2,4-dicarbonsäurediamide, Verfahren zu deren Herstellung sowie deren Verwendung
EP0596326B1 (de) Aryliden-1-azacycloalkane und Arylalkyl-1-azacycloalkane, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
EP0233483A2 (de) Pyrrolo[1,2-a][4,1]benzoxazepine, Verfahren zur ihrer Herstellung, pharmazeutische Präparate enthaltend diese Verbindungen, sowie therapeutische Verwendung
DE3028064C2 (cg-RX-API-DMAC7.html)
AU2001285894A1 (en) Prodrugs to NMDA receptor ligands
EP0212551A2 (de) Neue Tetraoxoverbindungen
DE2656678C2 (de) 4-Amino-trans-decahydrochinolin-Derivate und Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE69304453T2 (de) Pyridin-Derivate und diese enthaltende pharmazeutische Zubereitungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition